論文業績

原著論文(欧文)

  1. Tomita N, Hotta Y, Ito H, Naiki-Ito A, Matsuta K, Yamamoto Y, Ohashi K, Hayakawa T, Sanagawa A, Horita Y, Kondo M, Kataoka T, Takahashi S, Sobue K, Kimura K. High Preoperative Serum Strontium Increase the Risk of Acute Kidney Injury after Cardiopulmonary Bypass, Clin Exp Nephrol. 2023 Apr;27(4):382-391.
  2. Ieda N, Nakamura A, Tomita N, Ohkubo K, Izumi R, Hotta Y, Kawaguchi M, Kimura K, Nakagawa H. A BODIPY-picolinium-cation conjugate as a blue-light-responsive caged group. RSC Adv. 2023 Sep 4;13(38):26375-26379.
  3. Horita Y, Asaoka M, Iida M, Kato H, Wachino C, Mitamura K, Ohashi K, Mimura Y, Hotta Y, Kataoka T, Nakamura A, Kimura K. Development and Evaluation of a Novel Software Program, SAKURA-TDM, for AUC-guided Vancomycin Dosing: A Short Communication. Therapeutic Drug Monitoring, 2023 Apr. 1;45(2): 245-250.
  4. Asaoka M, Horita Y, Wachino C, Kondo S, Hotta Y, Kataoka T, Sanagawa A, Hayakawa T, Nakamura A, Kimura K. Clinical Usefulness of the “MN Criteria” – the Clostridioides difficile Infection Severity Scoring System – in the Japanese Setting. Internal Medicine, 2023 Jan 1; 62(1): 59–67.
  5. Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K: Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. International journal of urology, 2023 Oct;30(10):866-874.
  6. Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Odagiri K, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Furukawa-Hibi Y, Takahiro Yasui: Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International journal of urology, 30: 754-761, 2023.
  7. Sugiyama Y, Naiki T, Tasaki Y, Mimura Y, Etani T, Noda Y, Nozaki S, Shimizu N, Banno R, Nagai T, Isobe T, Ando R, Moritoki Y, Kataoka T, Odagiri K, Aoki M, Gonda M, Yasui T, Furukawa-Hibi Y: GNRI sustainability during one cycle of first-line chemotherapy as a prognostic indicator in patients with metastatic urothelial carcinoma. Oncology, 101: 224-233, 2023.
  8. Nakamura D, Yanagita T, Fujii Y, Watanabe K, Suzuki T, Ushigome H, Nishigaki R, Sugimura N, Tanaka M, Ogawa R, Takahashi H, Shimura T, Hotta Y, Matsuo Y, Kondo M, Furukawa-Hibi Y, and Takiguchi S: Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results. Surg Case Rep. 2024 May 1;10(1):105.
  9. Sanagawa A, Hayakawa T, Nishida E, Yamamoto A, Ikumi K, Mori Y, Hotta Y, Kimura K, Furukawa-Hibi Y, Morita A. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post-hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma. The Journal of Dermatology. 2023 Jul;50(7):917-926.
  10. Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, Kawakita D, Nakamura M, Ogawa R, Shimura T, Mimura Y, Hotta Y, Odagiri K, Ito N, Iida M, Kimura Y, Komatsu H, Kataoka H, Takiguchi S, Morita A, Iwasaki S, Okuda K, Niimi A, Yasui T, Furukawa-Hibi Y. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer Med. 2023 Nov 21.
  11. Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Iwatsuki S, Matsuyama N, Sue Y, Mimura Y, Odagiri K, Kubota H, Noda Y, Hashimoto Y, Sakakura T, Aoki M, Ikegami Y, Kobayakawa Y, Moritoki Y, Nozaki S, Takeda T, Kurokawa S, Okada A, Kawai N, Yasui T, and Kimura K. Elevated eosinophils as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. Int J Urol. 2023 Oct;30(10):866-874.
  12. Yamamoto Y, Kondo M, Hotta Y, Tashiro Y, Sanagawa A, Kataoka T, Furukawa-Hibi Y, Ri M, Komatsu H, Iida S, Kimura K. The relationship between changes in serum element concentrations and pathological condition and disease status in Japanese multiple myeloma patients: A pilot study and literature review. Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2493-2503.

 

原著論文(和文, 査読あり)

  1. 朝岡みなみ:愛知県病院薬剤師会医療安全対策委員会「術前中止薬の中止および再開忘れ防止に向けた現状調査(1)①外来・入院字における患者情報の収集②休薬に関する患者等への説明と同意」愛知県病院薬剤師会雑誌, 愛知県病院薬剤師会, 50巻3号33-37. 2023
  2. 朝岡みなみ:愛知県病院薬剤師会医療安全対策委員会「術前中止薬の中止および再開忘れ防止に向けた現状調査(2)③休薬する薬剤・期間に関する患者等への指導④入院時の休薬確認と休薬対象薬の再開忘れ防止」愛知県病院薬剤師会雑誌, 愛知県病院薬剤師会, 50巻4号24-29. 2023

 

著書・総説, 論文(英文, 査読あり)

  1. Kataoka T, Hotta Y, Kimura K. A review of experimental techniques for erectile function researches and development of medical technology using animal erectile dysfunction models in sexual and reproductive medicine. Reproductive Medicine and Biology. 22(1):e12513. 2023.

 

著書・総説, 論文(和文, 査読なし)

  1. 堀田祐志, 大山享也, 片岡智哉, 日比陽子, 木村和哲. 勃起と射精のメカニズムについて. 日本性機能学会雑誌. 38(1). 3-14. 2023.
  2. 堀田祐志, 片岡智哉, 日比陽子, 木村和哲. 下部尿路機能障害の治療を目指した光制御可能なNOドナーの開発. 日本排尿機能学会誌. 33(2).445-446. 2023.
  3. 堀田祐志, 家田直弥. 難治性勃起不全の新規治療薬を目指した光制御可能なNOドナーの開発. アグリバイオ. 7(3):73-77. 2023.
  4. 榊原諒子:術後疼痛管理チームにおける患者教育の重要性. LiSA,メディカル・サイエンス・インターナショナル,2023年9月.
  5. 榊原諒子:術後疼痛管理チームにおける薬剤師業務. 丸石製薬株式会社,2023年1月
  6. 片岡智哉, 堀田祐志, 日比陽子, 木村和哲. LOHに効果のある機能性食品. アンチ・エイジング医学. 19(3):024(222)-028(226). 2023.